HIV Vaccines

Clade B-Based Vaccine Induces Cross-Clade Immune Responses

Published in Vaccine Weekly, December 6th, 2000

A vaccine developed from clade B laboratory strains of HIV was shown to induce antibodies with cross-clade reactivity in a study conducted by U.S. Veterans Affairs researchers.

They point out that for an HIV vaccine to be useful across a number of geographic regions, it will need to exhibit such interclade immune responses.

F. Verrier et al. reported "strong immunochemical cross-reactivity with V3 peptides from clades B, C, and F" in patients who had been immunized with recombinant canarypox virus vCP205 and recombinant gp120(SF2). Antibodies in blood samples exhibited weaker activity against a number of V3 peptides from clades A, D, G, and H, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-12-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry